Suzanne Fussell, MD
Family Medicine · Oxnard, CANPI 1942394457
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (31.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Myovant Sciences Inc. at 28.2% of the total. Reporting peaked in 2022 at $7,369 and has fallen 85.2% since, to $1,090 in 2025. Among family medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 110 payments — averaging $190.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Myovant Sciences Inc.$6K
- Pfizer$5K
- GSK$3K
- Novartis$2K
- Modernatx, Inc.$2K
- Eisai Inc.$1K
- plus $2K from 19 others
Across 472 payments — averaging $18,738 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$2.5M
- Modernatx, Inc.$1.6M
- Amgen$1.3M
- Eisai Inc.$937K
- Novartis$624K
- Vertex$546K
- plus $1.4M from 14 others
What the payments were for
- Consulting fees$6,10029%
- Speaking & faculty fees$6,63032%
- Travel & lodging$4,45721%
- Food & beverage$3,69518%
- Education$320%
- Gifts$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Myovant Sciences Inc. | 2 | $5,895 |
| Pfizer | 14 | $4,978 |
| GSK | 1 | $2,500 |
| Novartis | 31 | $2,014 |
| Modernatx, Inc. | 4 | $1,949 |
| Eisai Inc. | 13 | $1,495 |
| Sumitomo Pharma America, Inc. | 1 | $450 |
| Exact Sciences | 6 | $330 |
| Cipher Pharmaceuticals US LLC | 1 | $285 |
| Lilly USA, LLC | 7 | $158 |
| Novo Nordisk | 5 | $150 |
| Sanofi Pasteur Inc. | 3 | $143 |
| Hologic Sales And Service, LLC | 5 | $125 |
| Boehringer Ingelheim | 1 | $123 |
| Abbott | 2 | $49 |
| Exeltis, USA Inc. | 2 | $47 |
| Genentech USA, Inc. | 3 | $44 |
| Boston Scientific | 1 | $43 |
| Gilead | 2 | $36 |
| Seqirus USA Inc | 1 | $25 |
| Nevro Corp. | 1 | $22 |
| Shield Therapeutics Inc | 1 | $20 |
| Vertiflex, Inc. | 1 | $18 |
| Bioventus LLC | 1 | $17 |
| Dexcom, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Belviq$1,155
- Natroba$285
- SPINOSAD$285
- The Cologuard Plus Collection Kit$239
- JARDIANCE$123
How this compares
$20,934 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 34 | $49,997 |
| JardianceEmpagliflozin | 27 | $34,597 |
| FarxigaDapagliflozin Propanediol | 25 | $27,615 |
| OzempicSemaglutide | 16 | $23,567 |
| XareltoRivaroxaban | 17 | $16,318 |
| MounjaroTirzepatide | 12 | $14,397 |
| EliquisApixaban | 11 | $13,779 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $5,757 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $5,421 |
| BelsomraSuvorexant | 11 | $5,062 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $2,798 |
| Lisdexamfetamine Dimesylate | 11 | $2,455 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 79 | $2,415 |
| Atorvastatin Calcium | 218 | $1,974 |
| Valsartan | 29 | $1,479 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat | $123 | $40,35439 claims |
| Novo NordiskOzempic | $150 | $23,56716 claims |
| Lilly USA, LLCMounjaro | $158 | $14,39712 claims |
| PfizerEliquis | $4,978 | $13,77911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.
Other family medicine in Oxnard
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Sandra CalmanMontara$589K
- Anthony JonesOakland$377K
- Amira AyadBakersfield$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.